Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2026-09-18 16:01:44 ET · period of report 2026-09-16 · accession 0001628280-26-062700 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-18 16:01 | 2026-09-16+ | CBIO | McNeill Jonathan | Pres, COO | S - Sale | $16.90 | -4,570 | 134.6K | -3% | -$77.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-09-16 | S | D | 731 | $17.90 | 138,427 | D | — | — | (F1) Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. (F2) The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 2 | Common | Ordinary Shares | 2026-09-18 | S | D | 3,839 | $16.71 | 134,588 | D | — | — | (F1) Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. (F2) The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |